Translatable Synaptic & Lipid Biomarkers for Early Parkinson’s: Insights from Longitudinal Multi-Modal Signatures

• Identifying novel plasma lipid and synaptic protein biomarkers that change longitudinally in early Parkinson’s, enabling earlier detection and patient stratification
• Correlating these biomarkers with clinical progression and functional decline to enhance predictive power in trial endpoints
• Enabling tighter selection and more efficient monitoring in clinical trials, reducing sample sizes and improving sensitivity to detect disease-modifying effects

Speakers:

Roman Loonis

Associate Medical Director, Clinical Sciences, Neurodegenerative Disorders

Takeda Pharmaceutical